- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265472
Comparison of Translocator Protein Expression and Binding Activity in Normal Tissue Versus Non Melanotic Malignancy
December 22, 2010 updated by: Rambam Health Care Campus
Comparison of the Expression Level of Translocator Protein (TSPO) and Binding Activity in Normal Cutaneous Tissue Versus Non Melanotic Cutaneous Malignancy.
Translocator protein (TSPO) is a intracellular protein that is found primarily in the outer membrane of the mitochondria that is encoded by the TSPO gene.
It has been found that TSPO expression in the skin correlates with cell proliferation and differentiation.
Many studies have shown that TSPO overexpression in solid malignancies such as in ovarian cancer, colon cancer, and others, was also found to correlate with more aggressive cancer behavior.
Working Hypothesis and Aims: Previous studies described an aberrant expression of TSPO levels in solid malignancies as compared to normal tissues.
It is assumed that this aberration can be found in cuntaneous malignancies as well.
The occurrence of this aberration may lead to the understanding of the mechanism of TSPO involment in the cutaneous malignancy, and in malignancies in general.
Methods: The study will be carried out on surgically resected skin lesions suspected to SCC or BCC, which will be removed as part of the surgical routine treatment.
The excision will be made in elliptic shape including the lesion and a part of normal skin surrounding it.
A sample will be taken from the central part of the lesion and from the external extremity of the normal tissue.
Western Blot will be conducted to detect the expression of TSPO.
Binding activity with the TSPO specific ligandwill also be determined.
Expected Results: We expect to observe either (a) a higher level of TSPO expression and a lower binding activity in malignant tissue compared with healthy control tissue or (b) a higher level of TSPO expression and a lower binding activity in malignant tissue compared with healthy control tissue.
Importance: Until today, only a very small number of studies have examined TSPO in cutaneous malignancies, and these only examined TSPO expression.
Our study will also measure the binding activity of TSPO in cutaneous malignant tissues compared to normal tissues
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Not an observational study.
Description
Inclusion Criteria:
- Clinical diagnosis of Basal Cell Carcinoma or Squamous Cell Carcinoma
Exclusion Criteria:
- Non-compliance with inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Anticipated)
June 1, 2011
Study Completion (Anticipated)
July 1, 2011
Study Registration Dates
First Submitted
December 22, 2010
First Submitted That Met QC Criteria
December 22, 2010
First Posted (Estimate)
December 23, 2010
Study Record Updates
Last Update Posted (Estimate)
December 23, 2010
Last Update Submitted That Met QC Criteria
December 22, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMB455-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterCompletedBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Daryoush Hamidi Alamdari, PhDEnrolling by invitationInoperable Disease | Advanced Basal Cell Carcinoma (BCC) | Morpheaform Basal Cell Carcinoma | Noduloulcerative Basal Cell Carcinoma | Infiltrative Basal Cell CarcinomaIran
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Christopher ZacharyActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
University of Michigan Rogel Cancer CenterRecruitingSkin Basal Cell CarcinomaUnited States
-
SkinJect, Inc.CompletedNodular Basal Cell CarcinomaUnited States, United Kingdom
-
BPGbioCompletedSuperficial Basal Cell CarcinomaUnited States